Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1717095

registered interest
date	10/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ritlecitinib: Shropshire
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when she expects Litfulo to be made available to NHS patients in (a) Shropshire, (b) Telford and (c) Wrekin.
tabling member constituency	The Wrekin
tabling member printed	Mark Pritchard
uin	25645
answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations on whether all new licensed medicines should be routinely funded by the National Health Service, based on an assessment of their costs and benefits.</p><p>On 27 March 2024, NICE published final technology appraisal guidance recommending ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years old and over. The NHS in England is legally required to fund medicines recommended by NICE within three months of the publication of its final guidance.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 14/05/2024 16:53:44 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1576 label Biography information for Mark Pritchard

1717160

registered interest
date	10/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Joint Replacements: Post-operative Care
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that best practice guidelines for prosthetic infection are implemented across elective surgery clinical care pathways.
tabling member constituency	Hayes and Harlington
tabling member printed	John McDonnell
uin	25605
answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>The Government is working with NHS England to improve perioperative care. This should ensure best practice guidelines are implemented across surgery clinical care pathways, including for prosthetic infections. In May 2023, NHS England published guidance setting out five core perioperative care requirements relating to the care of adult patients awaiting planned inpatient surgery. These measures address the key objective of identifying health needs as early as possible in perioperative pathways, and then using time on the waiting list to optimise health. The NHS England National Elective Recovery and Outpatients programme is working with NHS England regional teams to help oversee and support compliance, and will continue to do so throughout 2024/25.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 14/05/2024 16:56:42 answering member 4044 label Biography information for Andrew Stephenson
tabling member	178 label Biography information for John McDonnell

1716362

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Cancer: Artificial Intelligence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 May 2024 to Question 24269 on Lung Cancer: Artificial Intelligence, which (a) NHS trusts have and (b) imaging network has not received funding.
tabling member constituency	Hove
tabling member printed	Peter Kyle
uin	25291
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>Since the initial announcements regarding funding for National Health Service trusts to integrate artificial intelligence into lung cancer imaging, adjustments have been made to the list of participants. Three trusts have withdrawn from the initiative, and five additional trusts have been onboarded, due to the inclusion of a new imaging network. As a result, as set out in the answer of 7 May 2024, there are now 66 trusts across 12 imaging networks that are participating in this initiative.</p><p>In the answer of 7 May 2024, 63 out of 66 trusts, in 11 of 12 imaging networks, had received funding. It is now confirmed that all 66 trusts in the 12 imaging networks participating have received or are in the process of receiving funding. These trusts are currently implementing artificial intelligence technologies to enhance diagnostic capabilities in lung cancer, consistent with the Government's commitment to advancing healthcare technology across the NHS.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:24:50 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4505 label Biography information for Peter Kyle

1716421

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she (a) has had and (b) plans to have with (i) charities and (ii) other organisations working to secure UK access to new drugs for (A) incurable, (B) relapsing and (C) remitting cancers such as myeloma.
tabling member constituency	Birmingham, Yardley
tabling member printed	Jess Phillips
uin	25238
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>Department ministers and officials regularly meet with a range of organisations, with an interest in securing patient access to new cancer medicines. The National Institute for Health and Care Excellence (NICE) is the body that develops authoritative, evidence-based guidance for the National Health Service on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits, including medicines for myeloma. The NICE aims to publish guidance on all new medicines close to the point of licensing wherever possible, and has recommended many cancer medicines for NHS use that are now available to NHS patients, including through the Cancer Drugs Fund.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:43:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4370 label Biography information for Jess Phillips

1716422

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she (a) has had discussions and (b) plans to have discussions with the National Institute for Health and Care Excellence on (i) its use of the new severity modifier and (ii) how it (A) measures and (B) reports the impact of the modifier on approval of treatments for (1) cancers, (2) relapsing and remitting conditions and (3) conditions that are more prevalent in older people.
tabling member constituency	Birmingham, Yardley
tabling member printed	Jess Phillips
uin	25239
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>The Department regularly meets with colleagues in the National Institute for Health and Care Excellence (NICE) to discuss a range of issues, including in relation to the NICE’s methods for the evaluation of medicines. In 2022, the NICE introduced a number of changes to make its methods and processes fairer, faster, and more consistent. This includes the introduction of a broader severity modifier, in place of the end-of-life modifier. Since the changes were introduced, 79% of the NICE’s appraisals of cancer medicines carried out under the updated methods have recommended the use of the treatment for some or all of the eligible patient population, either for routine use or use through the Cancer Drugs Fund. The approval rate for all cancer appraisals carried out since 2009, when the end-of-life modifier was introduced, is 78%.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:48:27 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4370 label Biography information for Jess Phillips

1716489

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Steroid Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the implications for her policies of the long term prescribing of topical corticosteroids.
tabling member constituency	Morley and Outwood
tabling member printed	Dame Andrea Jenkyns
uin	25275
answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>In 2021 the Medicines and Healthcare products Regulatory Agency conducted a review and concluded that, when used appropriately, topical corticosteroids are a safe and effective treatment, and they continue to monitor the safety of these products. No further assessment has been made.</p><p>When making prescribing decisions for their patients, clinicians are expected to take into account best prescribing practice, in this case on the use of topical corticosteroids, alongside local commissioning decisions. The National Institute for Health and Care Excellence has made a number of recommendations on the use of topical corticosteroids in guidelines, on topics such as atopic eczema in under 12-year-olds, and psoriasis.</p><p>It is for the general practitioner or other responsible clinician to work with their patient and decide on the best course of treatment, with the provision of the most clinically appropriate care for the individual always being the primary consideration.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 14/05/2024 17:01:00 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4490 label Biography information for Dame Andrea Jenkyns

1716528

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Professions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help ensure public (a) safety and (b) clarity in the healthcare roles of (i) physician associates and doctors and (ii) other NHS staff.
tabling member constituency	South Swindon
tabling member printed	Sir Robert Buckland
uin	25215
answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>The introduction of regulation by the General Medical Council (GMC) will provide a standardised framework of governance and assurance for the clinical practice and professional conduct of Anaesthesia Associates (AAs) and Physician Associates (PAs), and make it easier for employers, patients, and the public to understand the relationship between these roles and that of doctors.</p><p> </p><p>Whilst statutory regulation is an important part of ensuring patient safety, it is also achieved through robust clinical governance processes within healthcare organisations, which are required to have systems of oversight and supervision for their staff.</p><p> </p><p>NHS England is working with the relevant professional colleges and regulators to ensure the use of associate roles is expanded safely and effectively, and that they are appropriately supported, supervised, and integrated into multidisciplinary teams. NHS England has written to trusts to remind them of their responsibilities in this area, with further information available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/long-read/ensuring-safe-and-effective-integration-of-physician-associates-into-departmental-multidisciplinary-teams-through-good-practice/" target="_blank">https://www.england.nhs.uk/long-read/ensuring-safe-and-effective-integration-of-physician-associates-into-departmental-multidisciplinary-teams-through-good-practice/</a></p><p> </p><p>We are clear that AAs and PAs are not, and should never be, referred to as medical practitioners, doctors, or consultants. It is the responsibility of professionals and their employers to ensure professional titles are used appropriately. As set out in the National Institute for Health and Care Excellence’s guidelines, all healthcare professionals directly involved in a patient's care should introduce themselves and explain their role to the patient. The GMC has published interim standards for AAs and PAs in advance of regulation, which make it clear that professionals should always introduce their role to patients and set out their responsibilities in the team.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 14/05/2024 16:54:09 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4106 label Biography information for Sir Robert Buckland

1716530

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Musculoskeletal Disorders: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help improve the (a) quality, (b) coverage, (c) availability and (d) use of musculoskeletal data.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	25259
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>The Office for Health Improvement and Disparities produces annual musculoskeletal health local profiles, designed to bring together meaningful data on a single platform, to enable the commissioning of high-value musculoskeletal services. Data is provided in a user-friendly format, to help local government and health services. They are regularly updated with relevant indicators, most recently in January 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 16:11:48 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1716532

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Joint Replacements: Surgery
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of people received treatment for (a) knee and (b) hip replacements in surgical hubs in each of the last 12 months.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	25261
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>NHS England has introduced specific hub-level data site codes for all operational hubs in 2023, with 89% of the 101 operational hubs now reporting data against these codes. However, as many of the hubs have only recently introduced the data codes, NHS England have limited data available for the last 12 months, and much of this new data submission is still being validated. Therefore, NHS England currently do not have reliable, validated hub-specific data about specific procedures undertaken in hubs.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:52:57 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1716533

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Records: Databases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress her Department has made on ensuring all NHS trusts have electronic patient records by March 2026.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	25262
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>The aim of the Frontline Digitisation programme is for all secondary care National Health Service trusts to have an Electronic Patient Record (EPR) system that meets our standards. The Government's 2023 mandate for NHS England set a target for 90% of NHS trusts to have an EPR system in place by December 2023, which has been met. The programme is forecasting to achieve 98% EPR coverage by March 2026, with the remaining 2% of NHS trusts advancing in their plans for an EPR.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 12:41:52 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell